Evidence map›Paper›PMID 41901314›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.

Linlin Wang, Arielis Rodriguez-Ulloa, Jorge Berlanga-Acosta, Ariana García-Ojalvo, Angel Abreu-Cruz, Luis Javier Gonzalez-López, Vladimir Besada-López, Yassel Ramos-Gómez, Gerardo Guillén-Nieto, Baohong Jiang

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Linlin WangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Arielis Rodriguez-UlloaCenter for Genetic Engineering and Biotechnology, Havana 10660, Cuba.ORCID 0000-0003-1566-4865
Jorge Berlanga-AcostaCenter for Genetic Engineering and Biotechnology, Havana 10660, Cuba.
Ariana García-OjalvoCenter for Genetic Engineering and Biotechnology, Havana 10660, Cuba.ORCID 0000-0002-9519-0139
Angel Abreu-CruzDepartment of Cardiology, Center for Surgical and Medical Research, Havana 10400, Cuba.
Luis Javier Gonzalez-LópezCenter for Genetic Engineering and Biotechnology, Havana 10660, Cuba.ORCID 0000-0002-8875-3642
Vladimir Besada-LópezCenter for Genetic Engineering and Biotechnology, Havana 10660, Cuba.ORCID 0000-0003-3584-7714
Yassel Ramos-GómezCenter for Genetic Engineering and Biotechnology, Havana 10660, Cuba.ORCID 0000-0003-3508-3830
Gerardo Guillén-NietoCenter for Genetic Engineering and Biotechnology, Havana 10660, Cuba.ORCID 0000-0003-3098-0970
Baohong JiangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Funding

China National Key R&D Program of China (2021YFE0111300)". 2021YFE0111300
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ejection fractionGHRP-6heart infarctionsystolic dysfunction

Identifiers

PMID41901314
PMCPMC13029777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.